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Background: Encapsulation of hydrophilic drugs within liposomes can be challenging.
Methods: A novel chitosan derivative, O-palmitoyl chitosan (OPC) was synthesized from chito-
san and palmitoyl chloride using methane-sulfonic acid as a solvent. The success of synthesis was 
confirmed by Fourier transform infra-red (FT-IR) spectroscopy and proton NMR spectroscopy 
(H-NMR). Liposomes encapsulating ferrous sulphate as a model hydrophilic drug for intestinal 
delivery were prepared with or without OPC inclusion (Lipo-Fe and OPC-Lipo-Fe). 
Results: Entrapment of iron was significantly higher in OPC containing liposomes compared to 
controls. Quantitative iron absorption from the OPC liposomes was significantly higher (1.5-fold 
P,0.05) than free ferrous sulphate controls. Qualitative uptake analysis by confocal imaging 
using coumarin-6 dye loaded liposomes also indicated higher cellular uptake and internalization 
of the OPC-containing liposomes. 
Conclusion: These findings suggest that addition of OPC during liposome preparation cre-
ates robust vesicles that have improved mucoadhesive and absorption enhancing properties. 
The chitosan derivative OPC therefore provides a novel alternative for formulation of delivery 
vehicles targeting intestinal absorption.
Keywords: gut delivery, intestinal absorption, Caco-2, ferrous sulfate
Introduction
Liposomes are formed from the spontaneous reordering and organization of phospholipid 
molecules in an aqueous medium that results in the formation of vesicles comprising 
one or more lipidic bilayers and an aqueous core.1 Bioactive molecules can either be 
encapsulated within the core, or incorporated within the phospholipid bilayer/bilayer 
interphase. Since they are composed of biologically similar lipids, liposomes are non-
toxic, biocompatible, and biodegradable as a carrier system.2 Liposomes thus represent 
an attractive delivery system for pharmaceutical applications where they can be utilized 
for targeted and controlled drug delivery, and in the cosmetic and food industry where 
the focus is on protection of the active ingredient and enhanced permeability and 
absorption.3,4 The lipid composition of liposomes can also affect the level of incorpora-
tion of drug/substances perhaps by affecting the packaging of vesicular bilayers.5
Although liposomes are capable of incorporating both hydrophilic and hydro-
phobic drugs, encapsulation of hydrophilic molecules is most challenging, partly 
due to loss of drug in the external aqueous phase during liposome formulation.6 This 
issue is further exacerbated in the case of ferrous iron whereby the metal iron–lipid 
interaction is known to have a detrimental effect on the integrity of the lipid bilayer.7 
Ferrous sulfate is a hydrophilic drug that is commonly used for iron supplementation 
therapy, most often via oral delivery. Its utility is severely limited by its ability to 
cause adverse gastrointestinal events.8,9 Others have also reported low iron absorption 
correspondence: satyanarayana 
somavarapu
Department of Pharmaceutics, Ucl 
school of Pharmacy, 29–39 Brunswick 
square, london Wc1N 1aX, UK
Tel +44 20 7753 5987
Fax +44 20 7753 5989
email s.somavarapu@ucl.ac.uk 
Journal name: International Journal of Nanomedicine
Article Designation: Original Research
Year: 2018
Volume: 13
Running head verso: Zariwala et al
Running head recto: Hydrophobically modified chitosan nanoliposomes for intestinal drug delivery
DOI: 166901
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
16
1.
74
.2
20
.1
93
 o
n 
28
-N
ov
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5838
Zariwala et al
from lipid-based iron delivery products when used as oral 
iron supplements.10
The polycationic biopolymer chitosan has been 
explored and employed in a number of liposome systems to 
improve their physiochemical stability and cellular uptake 
characteristics.11–15 Chitosan is a natural polysaccharide 
obtained by alkaline deacetylation of chitin, the major com-
ponent of crustacean shells.16 It has an excellent biocompat-
ibility profile due to its biodegradable nature; within the body 
it is metabolized by a number of enzymes (eg, lysozyme, 
di-N-acetyl chitobiase, N-acetyl-beta-d-glucosaminidase, 
and chitotriosidase).17,18 In addition, chitosan has strong 
mucoadhesive properties due to the presence of amine 
groups in its structure, which lead to electrostatic interac-
tions with the negatively charged cell surfaces, with resultant 
bioadherence.19,20 Chitosan coating onto the surface of micro 
or nanoparticles is therefore frequently used as a strategy 
to facilitate increased gastrointestinal uptake.21,22 Surface 
coating of liposomes with chitosan has also been shown to 
improve vesicle stability. Chitosan adsorbs strongly on the 
vesicle surface due to interplay between its amine groups and 
the negatively charged phospholipid polar heads.23 Unmodi-
fied chitosan, however, is limited in that the surface coating 
it forms on the liposomes is prone to rapid degradation in 
the gastric environment, thus affecting vesicle integrity 
and impairing the utility of these carriers for oral delivery 
applications.7
Chitosan is soluble only in dilute acids, which limits 
formulation approaches and hence its applications.11 Several 
studies have sought to improve the physical and chemical 
characteristics of chitosan by conjugating hydrophobic or 
hydrophilic moieties to its structure, such as alkyl groups, 
poly (ε-caprolactone), and poly (ethylene glycol) (PEG).24,25 
Acylation of chitosan can be carried out at the amino (NH
2
) 
group, the hydroxy (OH) group, or at both (N, O acyl 
chitosan) to obtain hydrophobic derivatives that are soluble 
in organic solvents such as chloroform, acetone, and dichlo-
romethane. These chemical modifications have led to the 
development of novel chitosan derivatives that have further 
widened its drug delivery applications.
In this study, we synthesized and characterized a novel 
hydrophobic chitosan derivative, O-palmitoyl chitosan 
(OPC), and used this to formulate liposomes loaded with 
ferrous sulfate as a model hydrophilic drug. Cytotoxicity, 
as well as qualitative and quantitative drug uptake from the 
liposomes, was evaluated in vitro using the human intestinal 
cell line Caco-2.
Materials and methods
Materials
Chitosan (chitosan oligosaccharide, molecular weight: above 
5k by viscosity method) was obtained from Kitto Life Co., 
Seoul, Korea, and egg phosphatidylcholine (egg PC) was 
obtained from Lipoid (Ludwigshafen, Germany). Palmitoyl 
chloride, ferrous sulfate, coumarin-6, cholesterol, and all 
other chemicals, reagents, and solvents were of analytical 
or cell culture grade, and purchased from Sigma-Aldrich 
(Gillingham, UK). Caco-2 cells were purchased from 
European Collection of Cell Cultures (catalog no. 09042001; 
ECACC, Salisbury, UK). Ferritin ELISA Kit (product 
code S-22) was from Ramco (ATI Atlas, Chichester, UK) 
and BCA Protein Assay Kit (product no. 23225) was from 
Pierce (Thermo Fisher Scientific, Basingstoke, UK). Cell 
culture media, fetal calf serum (FCS), and reagents were 
from Thermo Fisher Scientific. Cell Culture Plasticware 
was purchased from Nunc (Roskilde, Denmark) or Corn-
ing (Amsterdam, the Netherlands). All reagents used were 
prepared using ultrapure water (resistivity of 18.2 MΩ cm). 
Prior to use, all glassware and utensils were soaked in 10% 
HCl and rinsed with ultrapure water to remove any potential 
traces of residual minerals.
Methods
synthesis of O-palmitoyl chitosan
OPC was synthesized from chitosan and palmitoyl chloride 
using methanesulfonic acid as a solvent in order to protect 
the amino groups of chitosan. Chitosan was dissolved in 
methanesulfonic acid at room temperature for 1 hour and 
palmitoyl chloride was added dropwise with continuous 
stirring. The molar ratio of the repeating unit of chitosan to 
palmitoyl chloride was 1:2. The reaction mixture was kept 
under stirring conditions for 5 hours, before terminating 
the reaction by adding crushed ice. The resultant mixture 
contained OPC along with residual products such as unre-
acted chitosan, unreacted palmitoyl chloride, and chitosan 
reacted with methanesulfonic acid. Methanesulfonic acid was 
removed using sodium bicarbonate while the other impuri-
ties were removed using dichloromethane and chloroform to 
extract OPC from the mixture. Organic solvents were then 
evaporated using a rotary evaporator (Hei-VAP Advantage 
Rotary Evaporator, Schwabach, Germany) and the product 
dialyzed against distilled water for 2–3 days using dialysis 
tubing of molecular weight cutoff 7,000 Da (membrane size 
7,000/3, diameter 28 mm; Medicell International, London, 
UK). The dialyzed product was then lyophilized for 24 hours 
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(-40°C) using a VirTis AdVantage 2.0 bench top freeze dryer 
(SP Industries, Genevac, UK) to obtain pure OPC.
Polymer characterization
h-NMr spectroscopy
Proton NMR spectroscopy was performed on OPC using a 
Bruker 400 Ultra Shield spectrometer (Bruker, Coventry, 
UK). For measurements, chitosan was dissolved in deuterium 
oxide (D
2
O) and OPC was dissolved in deuterated chloroform 
(CDCl
3
), and spectra were obtained at room temperature.
Fourier transform infra-red spectroscopy
Fourier transform infra-red (FT-IR) spectra were collected at 
room temperature using a Perkin Elmer Spectrum 100 spec-
trometer (Perkin Elmer, Buckinghamshire, UK). Data were 
analyzed using the Perkin Elmer Spectrum Express software 
(Perkin Elmer).
Differential scanning calorimetry
In order to determine the thermal properties of the reactant, 
chitosan, and the product, OPC, differential scanning calo-
rimetry (DSC) experiments were performed using a DSC 
Q2000 module (TA Instruments, New Castle, DE, USA). 
Samples of approximately 5 mg (accurately weighed) were 
loaded onto aluminum hermetic pans. The thermal properties 
of chitosan were studied at a scan rate of 50°C/min and OPC 
was studied at 10°C/min. Both the materials were heated 
from -20°C to 200°C–300°C under a nitrogen atmosphere.
X-ray powder diffraction
The solid state properties of chitosan and OPC were measured 
by powder X-ray diffraction (XRD) studies using an Oxford 
Diffraction Xcalibur nova T X-ray diffractometer (Agilent 
Technologies, Wokingham, UK), which were processed 
using CrysAlis Pro software (Oxford Diffraction, Oxford, 
UK) and scanned at a step size of 10°2-theta.
Preparation of iron-loaded liposomes
Blank and iron-loaded liposomes were prepared by the thin-
film hydration method, with some modifications.26 Egg PC 
(200 mg) and cholesterol (20 mg) were dissolved in a round-
bottomed flask containing 5 mL chloroform. OPC (20 mg) 
was simultaneously dissolved in the chloroform for prepa-
ration of OPC liposomes. Organic solvent was removed 
using a rotary evaporator (Hei-VAP Advantage Rotary 
Evaporator) under reduced pressure (10 minutes, 60°C) 
yielding a lipid film on the walls of the flask. The lipid film 
was hydrated by adding a prewarmed aqueous ferrous sulfate 
solution dropwise and shaking the flask vigorously while 
maintaining at 60°C. The lipid suspension was then trans-
ferred into a glass vial and agitated gently in an ultrasonic 
bath for 3 minutes after which size reduction was performed 
using a probe sonicator (80% sonication power, 20 seconds 
on and off intervals). The samples were allowed to stand 
for 1 hour, followed by centrifugation to remove the unen-
trapped drug. The four liposome formulations prepared – 
blank liposome (Lipo-blank), iron-containing liposomes 
(Lipo-Fe), liposomes incorporating OPC (OPC-Lipo), and 
iron-containing OPC-liposomes (OPC-Lipo-Fe) – were 
stored in nitrogen purged glass vials at 4°C. For uptake 
visualization studies coumarin-6-loaded liposomes (Lipo-
Cou and OPC-Lipo-Cou) were prepared using a similar 
methodology.
Determination of entrapment efficiency
Iron entrapment efficiency (EE) was determined as described 
previously.27,28 Briefly, liposome preparations were centri-
fuged (13,000 rpm, 30 minutes, 4°C), and aliquots of the 
supernatant were collected to quantify unassociated drug. 
Ferrous iron levels in the solution were measured spectro-
photometrically at 572 nm using the ferrozine method.29 
Coumarin-6 concentration was determined using a microplate 
fluorimeter (Fluostar Optima; BMG Labtech, Ortenberg, 
Germany) at 450 nm/505 nm (excitation/emission). The mean 
values of three independent readings were recorded and the 
results were expressed as mean±SD.
EE was calculated using the following equation:
 
EE (%)
Unbound drug in supernatant
Total drug added
=
 
liposome physicochemical characterization
size analysis
Size distribution determination of the liposomes by dynamic 
light scattering (DLS) was carried out using the Zetasizer 
Nano ZS (Malvern Instruments, Malvern, UK). Prior to 
measurements the liposome dispersion was diluted using 
MQ H
2
O. All measurements were performed at 25°C, and 
three readings were taken for each sample to calculate mean 
particle size and standard deviation (SD).
Zeta potential
Zeta potential of the liposome dispersions was determined by 
measuring their electrophoretic mobilities using the Zetasizer 
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Nano ZS (Malvern Instruments). Measurements were carried 
out in triplicate at 25°C. All samples were diluted in water 
(1:10) before measuring the zeta potential.
cytotoxicity assay
The potential toxic effects of liposome formulations on 
Caco-2 cells were assessed by carrying out the colorimetric 
MTT assay, incubating Caco-2 cell monolayers with lipo-
some formulations diluted to final iron concentrations of 20, 
50, and 100 µM (and equivalent volumes of correspond-
ing blank liposomes) in phenol red free media for 48 and 
72 hours.28,30 Following incubation, 20 µL MTT (5 mg/mL) 
was added to each well and the plates were incubated for 
a further 4 hours. Media were then carefully aspirated and 
cell monolayers solubilized with DMSO (100 µL/well). The 
purple formazan product formed was quantified by measuring 
the absorbance spectrophotometrically at 550 nm to give an 
estimate of cell viability.
caco-2 cell iron absorption/quantitative cellular 
uptake
Caco-2 cells were obtained at passage 20 and used experi-
mentally between passages 35 and 55. Stock cultures were 
maintained in 75 cm2 tissue culture flasks in complete 
medium (DMEM – Glutamax®, pH 7.4 supplemented with 
10% FCS, 1% antibiotic/antimycotic solution, and 25 mM 
HEPES) in an incubator at 37°C in an atmosphere of 95% 
air and 5% CO
2
 at constant humidity. Caco-2 cell uptake 
experiments were carried out as described previously and 
lysed samples were stored for analysis.28,30 Total ferritin 
concentration of cell lysates was determined using a RAMCO 
ferritin ELISA kit following the manufacturer’s protocol 
with modifications.28 The protein content of Caco-2 cells was 
determined using the Pierce BCA kit following the manu-
facturer’s protocol. Ferritin concentration was standardized 
against total protein concentration, and ng ferritin/mg pro-
tein was considered an index of liposomal iron uptake and 
absorption by Caco-2 cells.
cellular uptake visualization/qualitative cellular 
uptake
Qualitative cellular uptake visualization studies were 
carried out as described previously with modifications.31 
The Caco-2 cell uptake experiment was carried out as 
described in the previous section, replacing Fe-loaded lipo-
somes with coumarin-6 liposomes (Lipo-Cou). Briefly, 
Caco-2 cell monolayers were washed twice with sterile 
Dulbecco’s phosphate buffered saline (DPBS), fixed with 
3% paraformaldehyde solution, and washed again twice with 
DPBS before cell permeabilization solution (0.5% Triton 
X-100 in DPBS) was added for 5 minutes. Cells were then 
washed again with DPBS before being incubated with a 5% 
BSA block solution containing RNAse A (final concentra-
tion 10 µL/mL). Cells were then incubated with Lipo-Cou 
and OPC-Lipo-Cou formulations diluted in DPBS at a con-
centration of 1 µg/mL for 2 hours at 37°C. Cell nuclei were 
stained with TO-PRO-3 (1 µM; Thermo Fisher Scientific) for 
1 hour at room temperature. Caco-2 cells were then exam-
ined under a confocal microscope (Leica TCS SP2; Leica 
Microsystems, Buckinghamshire, UK). The coumarin-6 and 
TO-PRO-3 were investigated at 488/520 and 642/661 nm 
wavelengths (excitation/emission), respectively. Images 
were analyzed using the Leica LCS Lite software suite 
(Leica Microsystems).
statistical analysis
Data are presented as mean±SD, and differences between 
samples were analyzed by one-way ANOVA followed by 
Tukey’s post hoc test using the PRISM software package 
(Version 6; Graphpad Software Inc., San Diego, CA, USA). 
Results were considered significantly different if P#0.05.
Results
The FT-IR spectra of chitosan and OPC are shown in 
Figure 1. The important peaks for chitosan are the broad 
peak from 3,200 to 3,500 cm-1, signifying the free hydroxyl 
and amine groups of chitosan; the small peak at 2,871 cm-1 
signifying the acyl groups; and the peak at 1,649 cm-1 sig-
nifying carbonyl stretching of an amide bond, suggesting 
acyl substitution at the amino group of chitosan. The low 
intensity of the peak suggests that the degree of acetylation 
of chitosan is low.32 The FT-IR spectrum of OPC differs 
from that of chitosan. The broad peak at 3,200–3,500 cm-1 is 
much reduced in OPC signifying substitution of the hydroxyl 
and amino groups of chitosan. There are two sharp peaks 
at 2,919 and 2,851 cm-1, which signify the palmitoyl (acyl) 
groups, indicating acylation of chitosan. The sharp peak at 
1,740 cm-1 signifies ester bond formation, which suggests that 
the substitution of the palmitoyl groups has occurred at the 
hydroxy groups of chitosan.33 The peak at 1,657 cm-1 signify-
ing amide bond formation is low in intensity, suggesting that 
the degree of N-acylation of chitosan is low.32 These FT-IR 
results confirm the successful synthesis of OPC.
The proton NMR (H-NMR) spectrum of chitosan 5k 
(Figure 2A) shows the characteristic peaks for chitosan, 
which occur between 1.8 and 5.2 ppm.33 The peak at 1.97 
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was assigned to the N-acetyl proton of N-acetyl glucosamine 
while the peak at 2.63 was assigned to a proton of N-acetyl 
glucosamine or glucosamine residues. The peaks from 3.3 to 
4.0 ppm were assigned to the ring protons and the peaks at 
4.38 and 4.40 ppm were assigned to protons of glucosamine 
and N-acetyl glucosamine, respectively.32 The peak at 
4.60 ppm is the D
2
O solvent peak. The H-NMR spectrum of 
OPC (Figure 2B) differs from that of chitosan. The peaks at 
0.86, 1.24, and 1.59 ppm were assigned to characteristic alkyl 
protons of the palmitoyl residue.33 The peak at 0.86 ppm was 
assigned to the protons of the terminal carbon of the alkyl 
chain, that is, [CH
3
-R] of the palmitoyl residue, while the 
peak at 1.24 ppm was assigned to the protons of the middle 
carbon, that is, [-CH
2
-] of the alkyl chain of the palmitoyl 
residue. The peak at 1.59 ppm was assigned to the protons of 
the carbon attached to the carbonyl carbon, that is, [-(CO)-
CH
2
-] of the palmitoyl residue.32 The peak at 7.24 ppm was 
the solvent peak for CDCl
3
. The H-NMR data thus confirm 
the formation of OPC.
The DSC thermogram of chitosan (Figure 3A) showed a 
small endothermic peak at 70.6°C and a broad endothermic 
peak at 100°C–150°C which indicate loss of unbound and 
bound water.34 There was also a sharp endothermic peak at 
243.5°C which indicates thermal degradation of the sample.35 
The DSC thermogram of OPC (Figure 3B) did not show any 
thermal transitions from 0°C to 160°C. The thermogram 
showed a sharp endothermic peak at 182°C, indicating 
polymer decomposition.36
The X-ray diffractogram of chitosan (Figure 4A) 
showed peaks at 2Θ=9, 20, and 23 which were charac-
teristics of chitosan.32,35 The diffractogram suggested that 
chitosan was crystalline. The X-ray diffractogram of OPC 
(Figure 4B) showed a broad peak at 2Θ=21. The peaks at 
2Θ=9 and 23 which were seen in chitosan have disappeared. 
Figure 1 FT-Ir spectra of chitosan 5k (red) and O-palmitoyl chitosan (black).
Abbreviations: FT-Ir, Fourier transform infra-red; T, transmittance.
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The diffractogram suggested that OPC was crystalline and that 
o-acylation had slightly altered the chitosan structure.35
Both the iron-containing liposome formulations demon-
strated high iron EE. The EE of Lipo-Fe was 72.8%±1.93%, 
which was increased and in case of OPC-Lipo-Fe, 
82.7%±2.70% (P,0.05; Table 1). Mean hydrodynamic 
diameters of all liposomes were in the range 204–304 nm 
following sonication (Table 1). Iron loading decreased mean 
particle size (P,0.05). Chitosan imparted a positive charge 
to the blank and iron-loaded liposomes, confirming its pres-
ence on the outer surface of the liposomes (Table 1), whereas 
liposomes without OPC had a net negative zeta potential. 
Iron loading affected the surface charge (P.0.05) of OPC-
containing liposomes, but decreased the negative surface 
charge of non-OPC liposomes (P,0.05), through an ionic 
interaction with the electric double layer.
Figure 2 h-NMr spectra of (A) chitosan 5k and (B) O-palmitoyl chitosan.
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Caco-2 cells were exposed to increasing concentrations 
of the liposome formulations standardized at specific iron 
concentrations (20, 50, and 100 µM elemental iron), as 
described previously.28,30 Cells were also incubated with 
iron-free liposome formulations to exclude the effect of iron. 
Cell viability in all cases was observed to be at least 85% 
of control cells at both the experimental time points (48 and 
72 hours; Figure 5).
To assess the efficacy of the liposome preparations to 
deliver iron intracellularly, comparative absorption experi-
ments were conducted (Figure 6) using the well-characterized 
human intestinal cell line Caco-2.37–39 Iron absorption from 
the liposome preparations was compared to that from free 
FeSO
4
 solution, as it is generally considered to have the 
best bioavailability profile among iron compounds and 
was employed in the preparation of the liposomal for-
mulation. The overall highest iron absorption was from 
OPC-Lipo-Fe liposomes (313.46±26.53 ng/mg protein) and 
was 1.5 fold (P,0.05) higher than for the free FeSO
4
 control 
(200.42±24.42 ng/mg protein).
The cellular uptake characteristics of the liposome for-
mulations were further evaluated qualitatively using confo-
cal microscopy. Figure 7 shows confocal micrographs of 
Caco-2 cells incubated with conventional (Lipo-Cou) and 
OPC liposomes (OPC-Lipo-Cou) loaded with equivalent 
concentrations of the fluorescent dye coumarin-6. The results 
suggest that the inclusion of the OPC influenced the surface 
charge of the liposomes. It is likely that the OPC was incor-
porated into the liposome structure due to the hydrophobic 
nature of the chitosan.
Discussion
Several previous studies have demonstrated the use of hydro-
phobic chitosan derivatives for formulating drug and gene 
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Figure 3 Dsc thermogram of (A) chitosan (50°c/min) and (B) O-palmitoyl chitosan (20°c/min).
Abbreviation: Dsc, differential scanning calorimetry.
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Figure 4 X-ray powder diffractograms of (A) chitosan and (B) O-palmitoyl chitosan.
Abbreviations: aDUs, analog digital units; deg, degrees.
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delivery carriers.40–44 In this study, a novel hydrophobically 
modified chitosan derivative was produced by conjugating 
palmitoyl to the chitosan backbone. The successful synthesis 
and formation of the reaction product OPC were determined 
by FT-IR and H-NMR, and the synthesized polymer was 
further characterized by DSC and XRD.
Liposomal-iron delivery has been explored previously; 
however, poor iron loading remains an issue. The permeability 
of the phospholipid bilayer of the lipid vesicles can lead to iron 
leakage and loss during formulation as well as upon storage. 
Various approaches have previously been explored to improve 
vesicle membrane stability. Inclusion of cholesterol in the for-
mulation increases membrane stability, resulting in increased 
encapsulation efficiencies.45–47 It is thought that the hydroxyl 
groups in the polar head combine with the choline groups of 
the lipid to create more robust bilayers.48 Cholesterol is also 
known to enhance contact between adjacent lipid molecules by 
having a “drying” effect at the lipid–water interface, thereby 
decreasing bilayer permeability and promoting liposomal 
membrane stability.49 PEGylated polyelectrolytes incorpo-
ration into liposomes similarly enhances drug delivery.50 
Chitosan incorporation in liposomes is known to have a posi-
tive influence on the encapsulation characteristics and delivery 
of liposomes.51–53 Chitosan adsorbs at the vesicle surface due 
to electrostatic interactions with the lipid component thereby 
creating rigid walled vesicles.54 Furthermore, chitosan report-
edly forms a stable complex with iron that might also result 
in higher incorporation and retention in the vesicle.55 The iron 
to lipid ratio is another important parameter that influences 
liposomal EE.28 This study employed an iron to lipid ratio of 
1:100, as increasing iron concentration has an inverse rela-
tionship with liposomal EE, an effect attributed to the strong 
electrolyte behavior of ferrous sulfate.6 OPC interacts with 
liposomes due to positive charge and hydrophobicity, which 
we propose is due to the conjugation of palmitoyl groups at 
the O position on the chitosan structure.
We aimed to obtain liposomes in the size range obtained 
(approximately 200–300 nm); it has been observed previously 
that large-sized liposomes are more likely to be unstable and 
have a tendency for flocculation.56 Furthermore, particles in 
the sub-500 nm range have been reported to be desirable 
for intestinal absorption as they facilitate increased cellular 
contact and permeation.57
The high net positive charge of the liposomes suggests 
electrostatic repulsion between the liposomes and is therefore 
considered favorable for formulation stability.58 Positive 
charge on the liposome surface is also beneficial for inter-
action and binding with cell surfaces, potentially leading to 
increased cellular entry and uptake.
The absorption results obtained in our experiments are 
in agreement with previous in vitro and in vivo liposome 
studies. Hermida et al demonstrated high iron uptake in 
Caco-2 cells from chitosan-coated liposomes compared with 
Table 1 Particle size distribution, surface charge, and entrapment 
efficiencies for liposome preparations
Formulation Mean particle 
size (nm)
Zeta 
potential 
(mV)
Entrapment 
efficiency 
(%)
lipo-blank 253±17 -28.6±8.77
lipo-Fe 204±22 -9.82±4.33
OPc-lipo 304±15 33.1±6.39 72.8±1.93
OPc-lipo-Fe 209±12 27.8±8.67 82.7±2.7
Note: Values are presented as mean±sD, n=3.
Abbreviations: Fe, iron; lipo, liposome; OPc, octyl-palmitoyl chitosan.
Figure 5 caco-2 cell viability assessed by MTT assay following (A) 48 hours and (B) 72 hours incubation with liposome formulations containing increasing drug concentrations 
(mean±sD, n=6).
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Figure 6 Iron absorption by caco-2 cells incubated with liposome formulations: 
intracellular ferritin was measured as a marker of iron absorption by elIsa following 
22 hours of incubation after iron uptake experiments.
Note: results are shown as mean±sD (n=6), *Represents a significant difference (95%) 
between treatment and FesO4 alone. ^Represents a significant difference (95%) bet­
ween OPc liposomes and liposomes alone.
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Figure 7 confocal microscopy images of caco-2 cells following incubation with coumarin-6 loaded (A–C) conventional (lipo-cou) liposomes and (D–F) OPc liposomes 
(OPc-lipo-cou). 
Notes: Images (A and D) demonstrate cell nuclei stained with TO-PrO-3 (blue), images (B and E) show cell cytoplasm with accumulated liposomal coumarin-6, and images 
(C and F) show merged images. scale shown is 50 µM.
uncoated liposomes.7 The behavior of chitosan liposomes 
within the intestinal tract was studied by Takeuchi et al using 
the Wistar rat model.59 Rat intestines were examined follow-
ing administration of liposome preparations, with and without 
chitosan inclusion, resulting in the highest levels of retention 
and mucosal penetration observed with chitosan inclusion. 
Chitosan has well-characterized mucoadhesive properties due 
to its cationic structure, and also acts as a potent permeation 
enhancer, particularly in the pH environment encountered 
in the small intestine.60
Lipid-based carriers are known to possess high cellular 
permeability, presumably by virtue of ease of transport across 
the phospholipid bilayer of cell membranes.61 Furthermore, 
the size range of our liposome particles is favorable toward 
intestinal absorption. The influence of particle size on intes-
tinal absorption has been explored previously; it is generally 
thought that particles of 100–500 nm dimensions are most 
likely to diffuse through the submucosal layer and subse-
quently enter the cell via absorptive endocytosis.62
The intensity of intracellular green fluorescence emitted by 
coumarin-6 was considered a marker of uptake of the dye-loaded 
liposomes in Caco-2 cells, as described previously.31,63 Similar 
studies by others have demonstrated that free coumarin-6 does 
not internalize in Caco-2 cells, and therefore the intracellular 
fluorescent intensity is a direct indicator of the internalization 
of the dye-loaded liposomes.64,65 As observed in Figure 7, a 
green fluorescent signal was seen in both images, Figure 7B and 
E, indicating successful entry into the cell of coumarin-loaded 
liposomes; however, a noticeably stronger signal was observed 
in Caco-2 cells incubated with OPC-Lipo-Cou (Figure 7E) 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
16
1.
74
.2
20
.1
93
 o
n 
28
-N
ov
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5846
Zariwala et al
compared with Lipo-Cou (Figure 7B). Confocal imaging was 
performed under similar parameters (sensitivity, gain, and 
offset) to allow an unbiased comparison. These results are in 
agreement with the quantitative uptake data as measured by 
ELISA (Figure 6), and provide further supporting evidence 
that OPC has a beneficial effect on the cellular uptake and 
internalization characteristics of the liposomes.
While mechanistic studies of the internalization and 
intracellular behavior of the liposomes were not conducted 
as part of our experiments, others have suggested potential 
pathways of cellular uptake and transport. Oral micro and 
nanoparticle drug carriers may gain cellular and subsequent 
systemic entry via either transcellular or paracellular path-
ways. Paracellular transport is thought to be limited, as the 
tight junctions between the intestinal enterocytes have an 
average pore radius of 5 nm.66 Even under conditions of 
induced dilation with pharmacological agents or due to patho-
logical insults, these junctions may allow the passage of very 
small-sized molecules.67 It is speculated that lipid particles 
are internalized via transcytosis and endocytosis followed 
by physiological degradation and intracellular drug release 
and subsequent transport across the basolateral membrane. 
This model is consistent with our observations, with higher 
intracellular levels of coumarin-6 and ferritin protein for-
mation observed following loaded liposome administration 
compared with drug alone. These results suggest that the drug 
released from the liposome formulations is actively processed 
within the enterocyte following cellular liposome uptake.
Conclusion
The purpose of this article was to synthesize a hydrophobi-
cally modified chitosan derivative and utilize this to formu-
late liposomes for oral drug delivery, using iron sulfate as 
a model hydrophilic drug. OPC not only led to increased 
liposomal iron encapsulation efficiency, but also significantly 
increased iron absorption in Caco-2 cells. These results 
confirm that this chitosan derivative retains the characteristic 
permeation-enhancing properties of chitosan, and further-
more its inclusion in the liposome may have altered the 
vesicle microstructure and influenced greater interaction with 
cell membranes leading to increased cellular uptake.
In summary, our results present OPC polymer incorpora-
tion into liposomes to be utilized for micro- and nanodelivery 
systems, and demonstrate the potential of OPC liposomes as 
promising carriers for intestinal drug delivery.
Disclosure
The authors report no conflicts of interest in this work.
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